You are here

Quotient Limited to Report Fiscal Second Quarter 2018 Financial Results and Host Conference Call

JERSEY, Channel Islands, Oct. 17, 2017 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company, today announced that financial results for its fiscal second quarter ended September 30, 2017, will be released after market close on Monday, October 30, 2017.

Quotient will host a conference call on Tuesday, October 31, 2017 at 8:30 a.m. Eastern Time to discuss its fiscal second quarter 2018 financial results. Participants may access the call by dialing 1-877-407-0784 in the U.S. or 1-201-689-8560 outside the U.S. The conference call will be webcast live on the Company's website at www.quotientbd.com.

A replay of this conference call will be available through November 7, 2017 by dialing 1-844-512-2921 in the U.S. or 1-412-317-6671 outside the U.S. The replay access code is 13672301.

About Quotient Limited

Quotient is a commercial-stage diagnostics company committed to reducing healthcare costs and improving patient care through the provision of innovative tests within established markets. With an initial focus on blood grouping and serological disease screening, Quotient is developing its proprietary MosaiQ™ technology platform to offer a breadth of tests that is unmatched by existing commercially available transfusion diagnostic instrument platforms. The company's operations are based in Edinburgh, Scotland; Eysins, Switzerland and Newtown, Pennsylvania.

The Quotient logo and MosaiQ™ are registered trademarks or trademarks of Quotient Limited and its subsidiaries in various jurisdictions.

CONTACT: Christopher Lindop, Chief Financial Officer — christopher.lindop@quotientbd.com; +41 (0)799 61 69 38

 

Tuesday, October 17, 2017 - 08:00

More Headlines

Some see the loss of an important, unbiased source of information.
Insurers are proceeding cautiously, but the large insurers are speeding up their approvals.
The move is considered part of the antiterrorism effort.
An impurity has been found to be carcinogenic.
But diabetes group tamp down expectations.
Agency says products for sexual enhancement, weight loss, and bodybuilding have hidden drugs and chemicals.
A meta-analysis that included 18 million participants found no protection from heart disease or stroke.
There is a small difference between them and biosimilars that physicians, patients, and insurers should be aware of.
It will nearly quadruple within the next five years, according to a new report, though concerns about how they’re manufactured remain.